Often, tumor cells upregulate surface ligands of receptors, also called immune checkpoints (including the CTLA-4/CD80, CD86 and PD-1/PD-L1, PD-L2 ligand/receptor pairs), that normally keep in check excessively activated T cells (Buchbinder and Desai, 2016). This evidence concerns the gene PDCD1 and neoplasm.